Entry Point Capital, LLC Arcutis Biotherapeutics, Inc. Put Options Transaction History
Entry Point Capital, LLC
- $68.4 Billion
- Q2 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding ARQT
# of Institutions
197Shares Held
128MCall Options Held
5.43MPut Options Held
257K-
Jennison Associates LLC11.7MShares$126 Million0.07% of portfolio
-
Suvretta Capital Management, LLC New York, NY10MShares$108 Million3.89% of portfolio
-
Rubric Capital Management LP New York, NY9.82MShares$106 Million2.7% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$95.1 Million4.82% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$93.3 Million0.0% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $651M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...